These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15901207)

  • 1. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents.
    Granberry MC; Fonseca VA
    Am J Cardiovasc Drugs; 2005; 5(3):201-9. PubMed ID: 15901207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
    Papanas N; Maltezos E
    Curr Pharm Des; 2009; 15(27):3179-92. PubMed ID: 19754390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
    Stolar MW; Chilton RJ
    Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
    Pfützner A; Forst T
    Expert Opin Pharmacother; 2006 Mar; 7(4):463-76. PubMed ID: 16503818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone: a review of its use in type 2 diabetes mellitus.
    Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
    Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of type 2 diabetes. Critical evaluation of oral antidiabetic drugs].
    Landgraf R
    MMW Fortschr Med; 2000 May; 142(21):33-7. PubMed ID: 10872292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular manifestations of insulin resistance.
    Chahwala V; Arora R
    Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Hypoglycemic Drugs by Liquid Chromatography-Tandem Mass Spectrometry.
    Jannetto PJ; Langman LJ
    Methods Mol Biol; 2024; 2737():297-306. PubMed ID: 38036831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease.
    Fonseca VA
    Am J Cardiol; 2003 Aug; 92(4A):50J-60J. PubMed ID: 12957327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral pharmacologic management of type 2 diabetes.
    Riddle MC
    Am Fam Physician; 1999 Dec; 60(9):2613-20. PubMed ID: 10605995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent effects of various diabetes drugs on cardiovascular prognosis.
    Bell DS; Patil HR; O'Keefe JH
    Rev Cardiovasc Med; 2013; 14(2-4):e107-22. PubMed ID: 24448252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2 diabetes: glycemic targets and oral therapies for older patients.
    Lardinois CK
    Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL; Faulds D
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
    Raptis SA; Dimitriadis GD
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S265-87. PubMed ID: 11460577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
    Lebovitz HE
    Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.